Andes-1537 for Injection

DRUG2 trials

Sponsors

Andes Biotechnologies

Conditions

Advanced Unresectable Solid TumorsCervical CancerColorectal CancerGall Bladder CancerGastric CancerPancreatic CancerTumor, Solid

Phase 1

Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors

TerminatedNCT02508441

Andes BiotechnologiesAdvanced Unresectable Solid Tumors

Start: 2015-12-08End: 2017-11-13Updated: 2018-10-18

Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor

CompletedNCT03985072

Andes BiotechnologiesCervical Cancer, Colorectal Cancer, Gall Bladder Cancer +3

Start: 2019-04-26End: 2022-02-17Updated: 2022-02-24

Related Papers

Phase 1 study of ANDES-1537: A novel antisense oligonucleotide against non-coding mitochondrial DNA in advanced solid tumors.

Journal of Clinical Oncology2018-05-2023 citations